药物相互作用临床试验在ClinicalTrials.gov注册与发表文章的安全性数据不一致:一项观察性研究
该观察性研究评估了ClinicalTrials.gov注册的药物相互作用(DDI)临床试验与对应期刊发表文章中的安全性数据一致性。在1,110项合格试验中,86.8%未在注册库报告结果,68.1%未发表;仅15.6%发表的不良事件数据与注册库完全一致。结论强调需加强监管要求以确保结果及时完整提交和不良事件报告一致性。
要点
- 多数DDI试验未在注册库报告结果(86.8%)或未发表(68.1%)。
- 仅15.6%发表的不良事件数据与注册库提交数据完全一致。
- 需修订并执行法规要求,确保结果及时完整提交和AE报告一致。
核心结论
- 发表文章中不良事件报告不完整或改变导致的数据差异,强调需修订并执行法规要求以确保结果及时完整提交、DDI试验更清晰AE报告,并在发表过程中定期评估AE数据一致性。
研究设计与样本
- 观察性研究,通过检索词「drug-drug interaction(s)」从ClinicalTrials.gov检索临床试验,收集注册信息和不良事件数据及对应发表文章,纳入主要研究DDI、有NCT标识且在2015年10月16日前关闭并完成的试验,发表数据提取至2017年3月。
主要发现
- 在1,110项合格试验中,76.8%为1期,68.8%由工业界资助,56.9%在注册前启动。
- 86.8%的试验未在注册库报告结果,68.1%未发表。
- 仅15.6%的试验发表AE数据与提交至ClinicalTrials.gov的数据完全一致。
- 在64项同时在注册库和发表文章中报告结果的试验中,34.4%发表的其他AE数量一致。
临床怎么用
- 提示临床医生和研究者关注DDI试验发表AE数据与注册库数据可能不一致,解读安全性信息时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess safety data of trials on drug-drug interactions (DDIs) reported in ClinicalTrials.gov and published in journal articles, since DDIs are a growing concern. STUDY DESIGN AND SETTING: In an observational study of clinical trials retrieved by the search term "drug-drug interaction(s)," we collected the information on registration and on adverse events (AEs) from ClinicalTrials.gov and corresponding publications. Trials were included if they primarily investigated DDIs, had a National Clinical Trial identifier, and were closed and completed by October 16, 2015. Publication data were extracted until March 2017. RESULTS: Among 1,110 eligible trials, most were in phase 1 (76.8%), industry-funded (68.8%), and started before registration (56.9%). Results were not reported in the registry for 86.8% and not published for 68.1% trials. Published AE data were completely identical to the data submitted to ClinicalTrials.gov for only 15.6% trials. Among 64 trials with results reported both in ClinicalTrials.gov and publications, 34.4% published concordant number for other AEs. CONCLUSION: Discrepancies that emerge from incomplete or changed reporting of AEs in publications emphasize the need to amend and enforce regulatory requirements for timely and complete submission of results, clearer AE reporting for trials focusing on DDIs, and regular assessment of the congruence of AE data submitted to ClinicalTrials.gov and scientific journals during the publication process.
引用
- Jurić D, Pranić S, Tokalić R, et al. Clinical trials on drug-drug interactions registered in ClinicalTrials.gov reported incongruent safety data in published articles: an observational study. J Clin Epidemiol. 2018. PMID: 30081071. doi:10.1016/j.jclinepi.2018.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。